NCT00689273已完成2 期
A 2-WEEK, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE 2, MULTICENTER STUDY OF PF-04136309 IN SUBJECTS WITH OSTEOARTHRITIC PAIN OF THE KNEE
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 159
- 试验地点
- 22
- 主要终点
- Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Domain Score at Week 2
研究概览
简要总结
To evaluate the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics in patients with osteoarthritic pain of the knee. The most painful knee joint will be identified as the index joint at screening, and this joint will be used for all pain assessments throughout the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female of any race, between the ages of 18 and 75 years inclusive
- •Female subjects must be of non-childbearing potential and have a negative pregnancy test at Screening.
- •Osteoarthritis of the knee of at least 6 months duration and meeting the American College of Rheumatology Criteria. For radiographic criteria the Xray must have been taken within the last 5 years. If none is available, one should be taken and the diagnostic criteria confirmed prior to randomization.
- •Willing and able to discontinue all current analgesic therapy, including OTC pain medications and topical analgesics for OA pain, for period beginning with washout phase (lasting 2 days or 5 half-lives of patient's current analgesic medication prior to Day -6) and continuing for the entire duration of study. As an exception, acetaminophen may be used for non-joint related pain at doses ≤1 g/day at the discretion of a qualified member of the study team.
- •If a subject has evidence or a history of clinically significant endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, renal, psychiatric, or neurological disease, the investigator must confirm that the disease is stable (at least 4 weeks) and under control.
- •QTc interval ≤450 msec and a PR interval ≤210 msec on Screening ECG.
排除标准
- •Pregnant or lactating females, and females of childbearing potential.
- •Arthroscopy performed on index knee within 1 year of screening.
- •Active depression as defined by or meeting The Hospital Anxiety and Depression Scale (HADS) of >
- •Unwillingness to refrain from consumption of grapefruit or grapefruit juice from 7 days prior to the first dose of study medication until completion of the study.
- •First degree or higher AV block, defined as PR interval >210 msecs, bundle branch block, fascicular block or intraventricular conduction delay or clinically relevant abnormality on screening ECG.
- •Active malignancy of any type or history of a malignancy within 10 years (with the exception of subjects with a history of treated basal cell carcinoma).
- •Symptomatic OA of the hip ipsilateral to index knee which the patient considers more painful than the knee.
- •Use of prohibited medications as listed below, in the absence of appropriate washout period. The following analgesic agents must be discontinued within 48 hours or 5 half lives of the analgesic being washed out prior to the baseline period (Day -6 to Day 0);
- •NSAIDs and selective COX-2 inhibitors;
- •Acetaminophen ( as an exception acetaminophen may be used for non-joint related pain at doses ≤1g/day);
- •Oral or I/M corticosteroids within 4 weeks prior to screening. I/A steroids within 12 weeks prior to baseline in study joint or any other joints within 4 weeks prior to baseline, or I/A hyaluronic acid within 24 weeks prior to baseline;
- •Use of concomitant medications that are CYP3A inhibitors or CYP3A inducers, or that are P-glycoprotein substrates within 48 hours or 5 half lives prior to baseline.
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
PF-04136309
Experimental
干预措施: PF-04136309 (Drug)
结局指标
主要结局
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Domain Score at Week 2
时间窗: Baseline, Week 2
WOMAC: self-administered, disease-specific 24 item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness, and physical function in participants with osteoarthritis (OA) of the hip and/or knee. It consists of 3 domains: pain, stiffness and physical function. WOMAC pain domain consists of 5 questions scored on 5 point Likert scale (0=minimum pain to 4=maximum pain) where higher score indicates higher pain. It assesses amount of pain experienced due to OA in the study joint in past 48 hours. Total possible pain domain score calculated by addition of scores of each 5 questions ranged from: 0 (minimum) - 20 (maximum), higher scores indicate higher pain.
次要结局
- Change From Baseline in WOMAC Physical Function Domain Score at Week 1 and Week 2(Baseline, Weeks 1, 2)
- Change From Baseline in WOMAC Total Score at Week 1 and Week 2(Baseline, Weeks 1, 2)
- Change From Baseline in WOMAC Pain Domain Score at Week 1(Baseline, Week 1)
- Change From Baseline in 11 Point NRS at Each Day From Day 1 to Day 14(Baseline, Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
- Change From Baseline in WOMAC Stiffness Domain Score at Week 1 and Week 2(Baseline, Weeks 1, 2)
- Change From Baseline in WOMAC Importance Weighted Total Score at Week 1 and Week 2(Baseline, Weeks 1, 2)
- Change From Baseline in 11 Point Numeric Pain Rating Scale (NRS) at Week 1 and Week 2 (Weekly Average)(Baseline, Weeks 1, 2)
- Number of Participants With at Least a 30 Percent (%) and 50% Reduction in Average Weekly Pain Score at Week 2: Last Observation Carried Forward (LOCF)(Baseline, Week 2)
- Change From Baseline in Patient's Global Assessment of Arthritic Condition at Week 1 and Week 2(Baseline, Weeks 1, 2)
研究者
研究点 (22)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular AtrophySpinal Muscular AtrophyNCT05794139NMD Pharma A/S52
已完成
1 期
A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With SchizophreniaSchizophreniaNCT02418819Pfizer103
已完成
2 期
Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With SchizophreniaSchizophreniaNCT05278156Celon Pharma SA189
已完成
2 期
A Safety PK/PD Study of SLV337 in Patients With Type 2 DiabetesType 2 DiabetesNCT00924534Abbott Products61
已完成
2 期
A Study of CDX-0159 in Patients With Chronic Inducible UrticariaChronic Inducible UrticariaNCT05405660Celldex Therapeutics196